Clinical Trials Browser

INDUSTRY × lazertinib × Clear all

NCT02609776 2026-04-13

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-04-13

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-04-13

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-04-13

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-04-13

COCOON

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-04-13

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT05541822 2025-05-22

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04075396 2025-04-29

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

29 enrolled 53 charts

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05862194 2023-08-22

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Approved for marketing

Lung Neoplasms